For Interventional Cardiologists
Final Results from the National Cardiogenic Shock Initiative (NCSI) Study Report Demonstrate Benefit of Early Impella Cardiac Unloading
The final results of the physician-led NCSI Study demonstrate a 71% survival to discharge with greater than 90% native heart recovery when best practices are used, including placement of an Impella heart pump prior to revascularization (PCI).
Explore the Latest Presented Data From the National Cardiogenic Shock Initiative (NCSI) Study
-
71%
Survival1
-
>90%
Native heart recovery at discharge1
NCSI Study is an independent, physician-led, national, multicenter initiative aimed at improving mortality in patients with AMI cardiogenic shock (AMICS).1 Based on the consistent finding of good survival outcomes with early hemodynamic support with Impella therapy from the IQ database and cVAD study, a best practices algorithm for the treatment of patients with AMICS was established. The NCSI Study algorithm includes identifying shock early, use of Impella therapy before PCI, reducing the use of inotropes, and the use of invasive hemodynamic monitoring to aid in escalation and weaning.
As of April 2021, 406 patients with AMI cardiogenic shock from 80 participating sites treated using Impella best practices demonstrated 71% survival at discharge with more than 90% native heart recovery.1
View Additional Resources
Conditions & Therapies
References
- Basir, B., et al. (2021). SCAI Scientific Sessions
NPS-1340